PMC5290639_01
Progressive recurrent pelvic disease resulting in hydronephrosis
40661_2017_38_Fig1_HTML.jpg
PMC5290639_01_40661_2017_38_Fig1_HTML.jpg
Fig1
Shortly thereafter, she was admitted for small bowel obstruction, with imaging revealing multifocal progression of the pelvic lesions (Fig. 1). Following cycle 2 of therapy, the patient was admitted for progressive pelvic pain due disease progression resulting in obstructive uropathy (Fig. 1).
Reduction in lesion size after starting nivolumab
40661_2017_38_Fig2_HTML.jpg
PMC5290639_01_40661_2017_38_Fig2_HTML.jpg
Fig2
After 2 doses, radiographic imaging demonstrated a decreased in size of all target lesions (Fig. 2).
Complete resolution of all lesions after 6th dose of nivolumab
40661_2017_38_Fig3_HTML.jpg
PMC5290639_01_40661_2017_38_Fig3_HTML.jpg
Fig3
PET/CT obtained 3 weeks after the final dose demonstrated complete resolution of all target and non-target lesions (Fig. 3).